This Article Full Text Full Text (PDF) All Versions of this Article: 1055-9965.EPI-07-2567v1 17/1/73    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McCullough, M. L. Articles by Calle, E. E. Search for Related Content PubMed PubMed Citation Articles by McCullough, M. L. Articles by Calle, E. E.

Body Mass and Endometrial Cancer Risk by Hormone Replacement Therapy and Cancer Subtype

¹ Epidemiology and Surveillance Research, ² Health Promotions, American Cancer Society, Atlanta, Georgia; ³ The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey; and ⁴ School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey

Requests for reprints: Marji McCullough, Epidemiology and Surveillance Research, American Cancer Society, 250 Williams Street, Suite 600, Atlanta, GA 30303-1002. Phone: 404-929-6816; Fax: 404-327-6450. E-mail: marji.mccullough{at}cancer.org

Epidemiologic studies unequivocally show that greater body mass increases the risk of endometrial cancer, but whether risk varies by use of postmenopausal hormone therapy (HT), location of fat deposition, or cancer subtype is still unclear. We examined these associations among 33,436 postmenopausal women in the Cancer Prevention Study II Nutrition Cohort, who completed questionnaires on diet, lifestyle, and medical history at baseline in 1992. A total of 318 cases were eligible through June 2003. Cox-proportional hazards analyses were used to estimate multivariate-adjusted rate ratios (RR). As expected, adult body mass index (BMI) was a strong predictor of risk [RR, 4.70; 95% confidence interval (CI), 3.12-7.07 for BMI 35+ versus 22.5-25.0, P trend < 0.0001]. Use of estrogen plus progestin postmenopausal HT modified the association. Among never-users, risk was significantly linear across the entire range of BMI examined (RR, 0.51; 95% CI, 0.29-0.92 for <22.5 versus 22.5-25.0; RR, 4.41; 95% CI, 2.70-7.20 for 35 versus 22.5-25.0, P trend < 0.0001), but among ever estrogen plus progestin users, the association was not significant (P trend = 1.0; P interaction < 0.0001). We observed no difference in risk according to tendency for central versus peripheral fat deposition. Greater BMI (30 versus <25.0) increased risk of both "type I" (classic estrogen pathway, RR, 4.22; 95% CI, 3.07-5.81) and "type II" (serous, clear cell, and all other high grade) cancers (RR, 2.87; 95% CI, 1.59-5.16). The increased risk of endometrial cancer across the range of BMI in women who never used postmenopausal HT stresses the need to prevent both overweight and obesity in women. (Cancer Epidemiol Biomarkers Prev 2008;17(1):73–9)

This article has been cited by other articles:

				A. Dellas, G. Jundt, G. Sartorius, M. Schneider, and H. Moch Combined PTEN and p27kip1 Protein Expression Patterns Are Associated with Obesity and Prognosis in Endometrial Carcinomas Clin. Cancer Res., April 1, 2009; 15(7): 2456 - 2462. [Abstract] [Full Text] [PDF]